Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Gynecologic Oncology Group Stories

2014-04-17 08:28:08

Company also announces designation of Orphan Drug Status by FDA for VTX-2337 in Ovarian Cancer SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today announced that enrollment has been completed in GOG-3003 (NCT01666444), a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with Pegylated Liposomal Doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior...

2014-01-28 04:20:52

SEATTLE, Jan. 28, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio(TM) ) as maintenance therapy in ovarian cancer. "Although initial treatment is effective in putting this disease in remission, there is a high relapse rate for patients with ovarian cancer and there...

2013-08-20 23:23:18

The affiliation allows further collaboration to advance cancer research. Fort Myers, FL and Scottsdale, AZ (PRWEB) August 20, 2013 21st Century Oncology today announced it will more closely combine cancer research initiatives with Massachusetts General Hospital (MGH), the original and largest teaching affiliate of Harvard Medical School (HMS). Currently, 21st Century Oncology, the largest U.S. radiation therapy provider, conducts cancer research alongside MGH within the framework of the...

2013-06-03 08:29:35

Data Support Ongoing Phase 2 Study in Platinum Resistant Ovarian Cancer SEATTLE, June 3, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. in collaboration with the Gynecologic Oncology Group and the National Cancer Institute's Cancer Therapy Evaluation Program announced today that positive preclinical and clinical data of VTX-2337 in combination with Doxil(® )(pegylated liposomal doxorubicin) or paclitaxel in women with recurrent ovarian cancer were presented at the American...

2013-03-19 16:29:17

HUNTSVILLE, Ala., March 19, 2013 /PRNewswire/ -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer. The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, Inc. Dr. Premal Thaker, of...

2013-01-31 04:21:35

SEATTLE, Jan. 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIO(TM )(paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis. CTI remains blinded to the interim analysis results. GOG-0212...

2012-12-06 05:04:24

Fellowship trained in treating cancers of the female reproductive system, Burton's expertise further enhances the wide range of Gyn Oncology services available at Abington Memorial Hospital. Abington, PA (PRWEB) December 06, 2012 Gynecologic Oncologist Elizabeth R. Burton, M.D., recently joined the staff of Abington Memorial Hospital´s Hanjani Institute for Gynecologic Oncology. Burton earned a Bachelor of Arts degree from Bowdoin College where she made the dean´s list for four...

2012-10-22 07:29:47

SEATTLE, Oct. 22, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. announced today the initiation of a randomized, placebo-controlled, Phase 2 trial evaluating VTX-2337 in combination with Doxil(®) (pegylated liposomal doxorubicin) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. The trial will investigate whether combining VTX-2337 with Doxil(®), a standard second-line...

2012-06-20 10:23:00

"Sandwiched" Sequencing of Chemotherapy and Radiation Resulted in More Than 80% Survival Rates in Early Stage Patients NEW YORK, June 20, 2012 /PRNewswire-USNewswire/ -- "Sandwich" therapy that uses chemotherapy and radiation treatment in sequence has been found to be extremely effective in treating aggressive forms of uterine cancer, according to two concurrent Montefiore Medical Center studies. These studies support that the combination therapy delivered in a "sandwich" fashion is...

2012-04-03 06:26:00

CHICAGO, April 3, 2012 /PRNewswire-USNewswire/ -- Ronald D. Alvarez, MD, Professor and Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham (UAB), has been elected the 44th President of the Society of Gynecologic Oncology (SGO) at its 43rd Annual Meeting on Women's Cancer held March 24-27, 2012, in Austin, TX. "We are in the midst of evolutionary times and our members need to be prepared for the changes coming with health care reform," states Dr....